News
IDXG
4.500
-2.17%
-0.100
*Interpace Biosciences Withdraws Securities Offering Due to Current Market Conditions
Dow Jones · 3d ago
Interpace Biosciences Q3 Revenue Rises 18%; Advances Pancreatic Cancer Program
NASDAQ · 4d ago
Interpace Biosciences GAAP EPS of -$0.26, revenue of $10.4M
Seeking Alpha · 5d ago
Weekly Report: what happened at IDXG last week (1109-1113)?
Weekly Report · 5d ago
Weekly Report: what happened at IDXG last week (1102-1106)?
Weekly Report · 11/09 10:03
Weekly Report: what happened at IDXG last week (1026-1030)?
Weekly Report · 11/02 10:03
Weekly Report: what happened at IDXG last week (1019-1023)?
Weekly Report · 10/26 10:03
Weekly Report: what happened at IDXG last week (1012-1016)?
Weekly Report · 10/19 10:03
Weekly Report: what happened at IDXG last week (1005-1009)?
Weekly Report · 10/12 10:07
Weekly Report: what happened at IDXG last week (0928-1002)?
Weekly Report · 10/05 10:07
Weekly Report: what happened at IDXG last week (0921-0925)?
Weekly Report · 09/28 10:03
U.S. IPO Weekly Recap: Postponed Deals Put Damper On Fall IPO Market
Seeking Alpha · 09/26 02:40
Weekly Report: what happened at IDXGD last week (0914-0918)?
Weekly Report · 09/21 10:03
Weekly Report: what happened at IDXGD last week (0907-0911)?
Weekly Report · 09/14 10:07
Weekly Report: what happened at IDXGD last week (0831-0904)?
Weekly Report · 09/07 10:02
Weekly Report: what happened at IDXGD last week (0824-0828)?
Weekly Report · 08/31 10:08
Interpace Biosciences announces 1-for-5 reverse split for Nasdaq uplisting
TipRanks · 08/26 20:50
*Interpace Biosciences Announces Reverse Stk Split to Support Proposed Nasdaq Uplisting
Dow Jones · 08/26 20:22
*Interpace Biosciences: Reverse Stk Split Will Become Effective at 12:01 AM ET on Aug 27 >IDXG
Dow Jones · 08/26 20:22
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Barchart · 08/26 15:05
More
Webull provides a variety of real-time IDXG stock news. You can receive the latest news about Interpace Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About IDXG
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.